Akifumi Onishi

Dr. Akifumi Onishi

Fukuyama City Hospital

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AOAyu Ogawa-Akiyama
Ayu Ogawa-Akiyama
HSHitoshi Sugiyama
Hitoshi Sugiyama
MKMasashi Kitagawa
Masashi Kitagawa
KTKeiko Tanaka
Keiko Tanaka
AOAkifumi Onishi
Akifumi Onishi
JWJun Wada
Jun Wada
Cystatin C is a cysteine protease inhibitor that is produced by nearly all human cells. The serum level of cystatin C is a stronger predictor of the renal outcome and the risk of cardiovascular events than the creatinine level. The resistive index (RI) on renal Doppler ultrasonography is a good indicator of vascular resistance as well as the renal outcomes in patients with chronic kidney disease (CKD). However, it is unclear whether serum cystatin C is associated with signs of vascular dysfunction, such as the renal RI. We measured the serum cystatin C levels in 101 CKD patients and investigated the relationships between cystatin C and markers of vascular dysfunction, including the renal RI, ankle-brachial pulse wave velocity (baPWV), intima-media thickness (IMT), and cardiac function. The renal RI was significantly correlated with the serum cystatin C level (p < 0.0001, r = 0.6920). The serum cystatin C level was found to be a significant determinant of the renal RI (p < 0.0001), but not the baPWV, in a multivariate regression analysis. The multivariate odds ratio of the serum cystatin C level for a renal RI of more than 0.66 was statistically significant (2.92, p = 0.0106). The area under the receiver-operating characteristic curve comparing the sensitivity and specificity of cystatin C for predicting an RI of more than 0.66 was 0.882 (cutoff value: 2.04 mg/L). In conclusion, the serum cystatin C level is an independent biomarker associated with the renal RI in patients with CKD.

Verified
Journal Article
Open access
PDF file
HMHiroki Maruyama
Hiroki Maruyama
ATAtsumi Taguchi
Atsumi Taguchi
MMMariko Mikame
Mariko Mikame
AIAtsushi Izawa
Atsushi Izawa
NMNaoki Morito
Naoki Morito
SISatoshi Ishii
Satoshi Ishii
Fabry disease is an X-linked disorder of α-galactosidase A (GLA) deficiency. Our previous interim analysis (1 July 2014 to 31 December 2015) revealed plasma globotriaosylsphingosine as a promising primary screening biomarker for Fabry disease probands. Herein, we report the final results, including patients enrolled from 1 January to 31 December 2016 for evaluating the potential of plasma globotriaosylsphingosine and GLA activity as a combined screening marker. We screened 5691 patients (3439 males) referred from 237 Japanese specialty clinics based on clinical findings suggestive of Fabry disease using plasma globotriaosylsphingosine and GLA activity as primary screening markers, and GLA variant status as a secondary screening marker. Of the 14 males who tested positive in the globotriaosylsphingosine screen (≥2.0 ng/mL), 11 with low GLA activity (<4.0 nmol/h/mL) displayed GLA variants (four classic, seven late-onset) and one with normal GLA activity and no pathogenic variant displayed lamellar bodies in affected organs, indicating late-onset biopsy-proven Fabry disease. Of the 19 females who tested positive in the globotriaosylsphingosine screen, eight with low GLA activity displayed GLA variants (six classic, two late-onset) and five with normal GLA activity displayed a GLA variant (one classic) and no pathogenic variant (four late-onset biopsy-proven). The combination of plasma globotriaosylsphingosine and GLA activity can be a primary screening biomarker for classic, late-onset, and late-onset biopsy-proven Fabry disease probands.

1 August 2019 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
HMHiroki Maruyama
Hiroki Maruyama
KMKaori Miyata
Kaori Miyata
MMMariko Mikame
Mariko Mikame
ATAtsumi Taguchi
Atsumi Taguchi
CGChu Guili
Chu Guili
SISatoshi Ishii
Satoshi Ishii
The PDF and HTML versions of the article have been updated to include the Creative Commons Attribution 4.0 International License information.

1 May 2023 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
KTKeiko Tanaka
Keiko Tanaka
HSHitoshi Sugiyama
Hitoshi Sugiyama
HMHiroshi Morinaga
Hiroshi Morinaga
AOAkifumi Onishi
Akifumi Onishi
YKYuzuki Kano
Yuzuki Kano
JWJun Wada
Jun Wada